Assuntos
Doenças do Cabelo/congênito , Neoplasias de Cabeça e Pescoço/diagnóstico , Nevo/diagnóstico , Neoplasias Cutâneas/diagnóstico , Pré-Escolar , Doenças do Cabelo/diagnóstico , Neoplasias de Cabeça e Pescoço/congênito , Humanos , Masculino , Nevo/congênito , Couro Cabeludo/anormalidades , Neoplasias Cutâneas/congênitoAssuntos
Histiócitos/metabolismo , Linfadenite Histiocítica Necrosante/induzido quimicamente , Linfadenite Histiocítica Necrosante/patologia , Linfonodos/patologia , Adulto , Diagnóstico Diferencial , Linfadenite Histiocítica Necrosante/terapia , Humanos , Masculino , Psoríase/tratamento farmacológicoRESUMO
Pilomatrixoma is a benign adnexal tumor very common in pediatric age and in young adults that derives from follicular matrix cells. Although clinically it usually presents as a subcutaneous nodule of bluish color less than 3cm in size, multiple clinicopathological variants have been described in the literature. Among these we can find the giant pilomatrixoma, a rare clinical variant that reaches a size greater than or equal to 4cm and can simulate the clinical presentation of a malignant neoplasm. We report a 59-year-old man with an exophytic and ulcerated nodule in the left parotid region that was removed with the suspected diagnosis of a cutaneous squamous cell carcinoma. Histopathological analysis showed a proliferation of basaloid cells with areas of transition to ghost cells, under granulation tissue, hemorrhage, and an ulcerated epidermis. Thus, the diagnosis of giant pilomatrixoma was made. We reviewed the literature and found a total of 53 articles that report a total of 71 cases of giant pilomatrixoma. It is important to recognize this clinical subtype of pilomatrixoma because, apart from the possibility of being clinically confused with malignant lesions, the clinicopathological differential diagnosis must be made with the proliferating pilomatrixoma and pilomatrixcarcinoma.
Assuntos
Doenças do Cabelo/patologia , Pilomatrixoma/patologia , Neoplasias Cutâneas/patologia , Diagnóstico Diferencial , Epiderme/patologia , Humanos , Masculino , Pessoa de Meia-IdadeAssuntos
Anti-Inflamatórios/efeitos adversos , Anticorpos Monoclonais Humanizados/efeitos adversos , Mucinoses/induzido quimicamente , Dermatopatias/induzido quimicamente , Feminino , Arterite de Células Gigantes/complicações , Arterite de Células Gigantes/tratamento farmacológico , Humanos , Pessoa de Meia-Idade , Mucinoses/patologia , Dermatopatias/patologia , Espondiloartropatias/complicaçõesAssuntos
Dermatite Alérgica de Contato/etiologia , Testes do Emplastro , Tiazóis/imunologia , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Adalimumab (ADA) is a recombinant human monoclonal antibody indicated for the treatment of psoriasis that specifically inhibits tumor necrosis factor. Until recently we only had the presentation of 40 mg of ADA, being the standard dose in adults an initial administration of 80 mg, followed by 40 mg every 2 weeks. Newly the presentation of 80 mg of ADA has been commercialized, allowing the administration of the standard dose or a higher dose, with fewer injections. In this study, we retrospectively studied 11 patients with psoriasis who have received treatment with the presentation of 80 mg of ADA in two dermatology departments of two hospitals in Spain since its commercialization until June 2019. At the end of the study, an improvement in the mean final Psoriasis Area Severity Index (PASI) of all patients was observed, without any patient presenting any adverse effects. This study shows the efficacy and safety of 80 mg of ADA in a sample of 11 patients with psoriasis.